Falguni Parikh
Papers
2
Total Citations
21
H-Index
2
About
Dr. Falguni Parikh is a leading translational researcher in head and neck oncology, with a focused expertise in immunotherapy for human papillomavirus-associated oropharyngeal cancer (HPVOPC). Her major contributions center on pioneering the use of live attenuated *Listeria monocytogenes*-based immunotherapy (ADXS11-001) to target HPV E7 oncoproteins. Through innovative "window of opportunity" clinical trials conducted prior to robotic surgery, Dr. Parikh demonstrated that this bacterial vector can effectively enhance HPV-specific T cell immunity within the tumor microenvironment. Her landmark 2016 study (19 citations) provided foundational evidence that neoadjuvant immunotherapy can prime the immune system against viral antigens, while her subsequent 2018 work (2 citations) explored the resulting shifts in local and peripheral T cell diversity. These investigations have been critical in establishing the feasibility and immunological rationale for combining bacterial-based vaccines with surgical resection. By directly measuring immune responses in patients undergoing standard-of-care treatment, Dr. Parikh’s research bridges preclinical promise with clinical application, offering a compelling strategy to improve outcomes for the growing population of HPV-driven oropharyngeal cancer patients.
Research Focus
Key Achievements
Top Papers
- 1
- 2